At median (range) follow-up of 46 (0-123) months, 299 of 723 patients (41.4%) had disease recurrence, including 165 patients (42.4% of baseline cohort) with EGFR-positive NSCLC and 134 patients (40.1% of baseline cohort) with wildtype EGFR NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.